Advanced knee arthritis patients facing joint replacement surgery may find meaningful relief through an unexpected source: their own blood. This development challenges the standard treatment hierarchy that typically reserves platelet-rich plasma as a last resort before surgery.
In a controlled trial of 90 patients with severe osteoarthritis awaiting knee replacement, two platelet-rich plasma injections delivered one week apart produced sustained pain reduction and functional improvement over six months. Participants experienced significant decreases in visual analog pain scores and comprehensive arthritis assessments compared to both corticosteroid injections and oral anti-inflammatory medications. Notably, the PRP group required substantially less opioid pain medication at the three-month mark, suggesting genuine therapeutic benefit rather than temporary symptom masking.
Beyond clinical improvements, blood analysis revealed favorable changes in multiple inflammatory and cartilage turnover biomarkers, including reduced levels of cartilage breakdown products and inflammatory cytokines. This dual evidence of symptomatic relief paired with biological improvement suggests PRP may address underlying disease processes rather than merely providing temporary comfort.
This finding represents a meaningful advance in treating end-stage arthritis, a condition affecting millions of aging adults. While knee replacement remains highly effective, surgical delays and patient preference for conservative treatment create significant demand for alternatives. The durability of PRP benefits through six months, combined with minimal adverse effects from using autologous blood products, positions this approach as a viable bridge therapy. However, the single-center design and relatively small cohort warrant larger multicenter trials to establish reproducibility across diverse patient populations and treatment protocols.